Jacqueline Capeau

6PUBLICATIONS
15CO-AUTHORS
Respiratory diseasesOrthodontics and dentofacial orthopaedicsCentral nervous systemAutoimmunityMajor global burdens of disease
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Mar 28, 2026
Different Trends of Immune Activation Markers When Switching to Either Oral or Injectable Dual Antiretroviral Therapy Based on Integrase Inhibitors in People Living with HIV.

Matteo Vassallo, Jacques Durant, Roxane Fabre

|Feb 05, 2026
Doravirine versus dolutegravir-based regimen in antiretroviral treatment-naive people living with HIV-1 (ANRS0392s ELDORADO): protocol for an international, open-label, randomised, non-inferiority, phase III trial.

Anthony L'hostellier, Charles Kouanfack, Corine Chazallon

|Jun 25, 2025
The Effects of High-Dose Probiotic Supplementation on Immune Activation and Neurocognitive Disorders in People Living with HIV Undergoing Successful Antiretroviral Treatment: The Procog Study.

Matteo Vassallo, Margaux Zerlini, Roxane Fabre

|Jun 10, 2022
Inhibition of Adipose Tissue Beiging by HIV Integrase Inhibitors, Dolutegravir and Bictegravir, Is Associated with Adipocyte Hypertrophy, Hypoxia, Elevated Fibrosis, and Insulin Resistance in Simian Adipose Tissue and Human Adipocytes.

Kenza Ngono Ayissi, Jennifer Gorwood, Laura Le Pelletier

|May 16, 2020
Progerin Expression Induces Inflammation, Oxidative Stress and Senescence in Human Coronary Endothelial Cells.

Guillaume Bidault, Marie Garcia, Jacqueline Capeau

|Jan 24, 2020
HIV antiretroviral drugs, dolutegravir, maraviroc and ritonavir-boosted atazanavir use different pathways to affect inflammation, senescence and insulin sensitivity in human coronary endothelial cells.

Martine Auclair, Anne-Claire Guénantin, Soraya Fellahi

Pageof 1

Frequent Collaborators

2 joint publications

Véronique Béréziat

2 joint publications

Roxane Fabre

2 joint publications

Soraya Fellahi

2 joint publications

Jean-Philippe Bastard